BioVectra opens new API manufacturing
Canadian biopharmaceutical company BioVectra has opened a new 33,500 sq ft cGMP facility on Prince Edward Island, Canada.
Canadian biopharmaceutical company BioVectra has opened a new 33,500 sq ft cGMP facility on Prince Edward Island, Canada.
Situated close to the biopharmaceutical centres of the eastern corridor of North America, the expanded cGMP capacity gives BioVectra commercial-scale manufacturing capability for APIs. The company also manufactures advanced intermediates, pre-clinical, and Phase I, II and III clinical trial supplies in milligram to multi-tonne quantities, and has the capability for high-potency compound projects, cytotoxics production, commercial-scale natural product extraction/purification and small-molecule organic synthesis.
BioVectra has 10 years of expertise in small-molecule isolation and purification using normal- and reverse-phase, size-exclusion, and ion-exchange commercial-scale chromatography.